GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Net Income (Continuing Operations)

Argenica Therapeutics (ASX:AGN) Net Income (Continuing Operations) : A$-4.67 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Argenica Therapeutics's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was A$-1.41 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-4.67 Mil.

Argenica Therapeutics Net Income (Continuing Operations) Historical Data

The historical data trend for Argenica Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Net Income (Continuing Operations) Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Net Income (Continuing Operations)
-1.03 -4.09 -4.82

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income (Continuing Operations) Get a 7-Day Free Trial -1.75 -2.35 -1.55 -3.26 -1.41

Argenica Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-4.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argenica Therapeutics  (ASX:AGN) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Argenica Therapeutics Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Argenica Therapeutics (ASX:AGN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Net Income (Continuing Operations)
Comparable Companies
ASX:NOX ASX:RAD ASX:EZZ ASX:PAA ASX:BIO ASX:ACW ASX:CYP ASX:1AI ASX:BTC ASX:IXC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Website
https://www.argenica.com.au
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines